Melanotan 1 (MT1) is a synthetic analogue of alpha-melanotocyte stimulating hormone. It is used clinically, in Europe, to prevent sun-related skin damage (i.e. phototoxicity) from occurring in people suffering from erythropoietic protoporphyria. Though initially developed as a sunless tanning agent, melanotan 1 has been found to have a number of physiologic effects on blood pressure, feeding behavior, central nervous system function, and more. The peptide is in phase 3 clinical trials for the treatment of polymorphous light eruption and is in phase 2 clinical trials for the treatment of actinic keratosis (a specific type of skin damage caused by the sun) and its more serious counterpart, squamous cell carcinoma.
For more information on MT1 Peptide read:
||Melanotan 1; MT1